Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genelux Corp (GNLX)

Genelux Corp (GNLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Genelux Corp 2625 Townsgate Road Suite 230 Westlake Village CA 91361 USA

www.genelux.com P: 805-267-9889

Description:

Genelux Corporation is a clinical-stage biopharmaceutical company. It focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus. Genelux Corporation is based in WESTLAKE VILLAGE, Calif.

Key Statistics

Overview:

Market Capitalization, $K 63,208
Enterprise Value, $K 53,788
Shares Outstanding, K 34,352
Annual Sales, $ 170 K
Annual Net Income, $ -28,300 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -7,850 K
EBIT, $ -25,830 K
EBITDA, $ -24,740 K
60-Month Beta -1.57
% of Insider Shareholders 9.30%
% of Institutional Shareholders 37.33%
Float, K 31,157
% Float 90.70%
Short Volume Ratio 0.59

Growth:

1-Year Return -94.77%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.29 on 05/09/24
Next Earnings Date 08/12/24
Earnings Per Share ttm -0.95
EPS Growth vs. Prev Qtr -16.00%
EPS Growth vs. Prev Year 67.74%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GNLX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -125.58%
Return-on-Assets % -86.03%
Profit Margin % -16,647.06%
Debt/Equity 0.00
Price/Sales 394.04
Price/Cash Flow N/A
Price/Book 3.47
Book Value/Share 0.56
Interest Coverage -165.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar